Medpace Holdings

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medpace Holdings reports robust Q4 earnings amidst challenging biotech environment

Medpace Holdings delivered strong financial results in Q4 2022, showcasing revenue and EBITDA growth. The company addressed challenges such as cancellations and client funding risks while emphasizing strategic selectivity and revenue growth. Opportunities for growth through share-taking strategies and operational improvements were highlighted.

Medpace Holdings reports stellar Q1 results and projects strong 2023 guidance

Medpace Holdings demonstrated robust financial performance in Q1 2023, marked by significant revenue growth, improved profitability, and a strong backlog conversion outlook.
While facing funding challenges, the company's strategic initiatives, including share repurchases and updated guidance, highlight its resilience and growth potential.
By capitalizing on increased RFP flow, program progression, and strong backlog metrics, Medpace aims to sustain its growth trajectory and enhance market position.

Medpace Holdings reports robust Q2 earnings and growth opportunities

Medpace Holdings (MEDP) delivered a strong Q2 performance with significant revenue growth, solid financial metrics, and a healthy backlog, positioning the company for future success.
While facing challenges related to customer concentration and operational aspects, Medpace can capitalize on opportunities to drive revenue expansion, enhance market share, and improve operational efficiency.
Overall, Medpace's Q2 earnings call reflects a positive outlook with a focus on growth strategies, operational excellence, and addressing potential challenges to drive long-term value for stakeholders.

Medpace Holdings reports robust Q3 performance and optimistic 2024 outlook

Medpace Holdings delivered strong financial results in Q3 2023, with notable revenue growth and increased backlog, despite modest EBITDA growth.
The company's operational strengths include robust demand, good retention rates, and a stable employee base, supporting its growth trajectory.
While facing potential challenges in managing rapid growth, Medpace Holdings has opportunities for expansion through market diversification and service enhancements.

Medpace Holdings reports robust Q4 earnings and outlines growth targets

Medpace Holdings delivered impressive financial results in Q4 2023, showcasing strong revenue growth, increased net income, and a healthy EBITDA, supported by new business awards and share repurchases.
While the company faces challenges in sustaining high growth rates and addressing uncertainties in project funding, its stable financial position and strategic initiatives provide a foundation for future growth.
With a positive outlook for 2024 and opportunities for expansion and market share gains, Medpace is well-positioned to navigate industry challenges and drive continued success in the clinical research sector.

Medpace Holdings reports robust Q1 performance and optimistic 2024 outlook

Medpace Holdings delivered impressive Q1 results, showcasing strong revenue growth and profitability metrics.
The company's strategic focus on efficiency and growth opportunities bodes well for future performance and sustained success.
While challenges exist, Medpace's positive outlook, stable funding environment, and strategic initiatives position it for continued growth and value creation.

Medpace Holdings reports robust Q2 growth despite project cancellations

Medpace Holdings delivered strong financial performance in Q2 2024, with notable revenue and EBITDA growth. While facing challenges with project cancellations impacting backlog, the company remains optimistic about its future prospects, driven by a robust pipeline of opportunities and strategic hiring plans.

Medpace Holdings reports strong Q3 earnings, eyes growth opportunities

Medpace Holdings delivered strong financial results in Q3 2024, with revenue growth, increased profitability, and a healthy backlog, setting a positive trajectory for future performance.
While facing challenges such as backlog cancellations and lower RFP flow, the company's stable pricing, strategic focus, and operational efficiency position it well for growth.
Opportunities lie in improving order intake, capital deployment optimization, and maintaining shareholder value through disciplined decision-making and market expansion.
Overall, Medpace Holdings' performance reflects resilience, strategic clarity, and potential for growth, underpinned by operational efficiency and financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NY / ACCESSWIRE / October 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ:MEDP) concerning possible violations of federal securities laws. Jefferies downgraded Medpace, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.

Medpace Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – MEDP

Medpace Holdings, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Medpace Holdings, Inc. (MEDP)

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Revenue for the three months ended September 30, 2024 increased 8.3% to $533.3 million, compared to $492.5 million for the comparable prior-year period. On a constant currency basis, revenue for the third quarter of 2024 increased 8.1% compared to the third quarter of 2023. Backlog as of September 30.

Medpace Holdings, Inc. Reports Third Quarter 2024 Results

NEW YORK, NY / ACCESSWIRE / October 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ:MEDP) concerning possible violations of federal securities laws. Jefferies downgraded Medpace, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.

Shareholder Rights Advocates at Levi & Korsinsky Investigate Medpace Holdings, Inc. (MEDP) Regarding Possible Securities Fraud Violations

NEW YORK, NY / ACCESSWIRE / October 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ:MEDP) concerning possible violations of federal securities laws. Jefferies downgraded Medpace, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.

MEDP STOCK ALERT: Levi & Korsinsky Notifies Medpace Holdings, Inc. Investors of an Ongoing Investigation

NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ:MEDP) concerning possible violations of federal securities laws. Jefferies downgraded Medpace, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Medpace Holdings, Inc. (MEDP)

Did Medpace Holdings, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- MEDP

MEDP Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, CA / ACCESSWIRE / October 14, 2024 / Hagens Berman urges Medpace Holdings, Inc. (NASDAQ:MEDP) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.

Medpace Holdings (MEDP) Reveals "Shocking" Bookings Miss, Shares Fall - Hagens Berman

NEW YORK, NY / ACCESSWIRE / October 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ:MEDP) concerning possible violations of federal securities laws. Jefferies downgraded Medpace, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.

An Investigation Has Commenced on Behalf of Medpace Holdings, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your MEDP Losses.

In the most recent trading session, Medpace (MEDP) closed at $347.91, indicating a +0.93% shift from the previous trading day.

Medpace (MEDP) Rises Higher Than Market: Key Facts

NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ:MEDP) concerning possible violations of federal securities laws. Jefferies downgraded Medpace, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.

Lost Money on Medpace Holdings, Inc.(MEDP)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ:MEDP) concerning possible violations of federal securities laws. Jefferies downgraded Medpace, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.

Investors who lost money on Medpace Holdings, Inc. should contact Levi & Korsinsky about an ongoing investigation - MEDP

Levi & Korsinsky Reminds Medpace Holdings, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - MEDP

NEW YORK, NY / ACCESSWIRE / October 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ:MEDP) concerning possible violations of federal securities laws. Jefferies downgraded Medpace, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.

Medpace Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - MEDP

NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ:MEDP) concerning possible violations of federal securities laws. Jefferies downgraded Medpace, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.

Levi & Korsinsky Reminds Shareholders of an Investigation into Medpace Holdings, Inc. (MEDP) Regarding Potential Securities Fraud Allegations

MEDP ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Medpace Holdings, Inc. investment

Medpace (MEDP) reachead $343.05 at the closing of the latest trading day, reflecting a +1.57% change compared to its last close.

Medpace (MEDP) Laps the Stock Market: Here's Why

Solventum Corporation

Investors with an interest in Medical Services stocks have likely encountered both Solventum (SOLV) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?

SOLV or MEDP: Which Is the Better Value Stock Right Now?

In the latest trading session, Medpace (MEDP) closed at $326.26, marking a +1.77% move from the previous day.

Medpace (MEDP) Outperforms Broader Market: What You Need to Know

NEW YORK CITY, NY / ACCESSWIRE / September 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP). Investors who purchased Medpace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MEDP.

Bronstein, Gewirtz & Grossman, LLC Encourages Medpace Holdings, Inc. (MEDP) Investors to Inquire about Securities Investigation

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2024 financial results after the market close on Monday, October 21, 2024. The Company will host a conference call the following morning, Tuesday, October 22, 2024, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you jo.

Medpace Holdings, Inc. to Report Third Quarter 2024 Financial Results on October 21, 2024

The latest trading day saw Medpace (MEDP) settling at $354.65, representing a -0.57% change from its previous close.

Medpace (MEDP) Stock Dips While Market Gains: Key Facts

LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medpace Holdings Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Invites Shareholder Participation

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Is Medpace (MEDP) a Buy as Wall Street Analysts Look Optimistic?

HealthEquity

Investors interested in stocks from the Medical Services sector have probably already heard of HealthEquity (HQY) and Medpace (MEDP). But which of these two companies is the best option for those looking for undervalued stocks?

News for Medpace Holdings Stock (MEDP)